Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 10/20 | 0.82 |
| ▸ | TMPRSS4 | Q9NRS4 | 9/20 | 0.72 |
| ▸ | P2RX4 | Q99571 | 5/20 | 0.69 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.69 |
| ▸ | KCNMA1 | Q12791 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | IKBKB | O14920 | 1/20 | 0.59 |
| ▸ | CHUK | O15111 | 1/20 | 0.59 |
| ▸ | KDR | P35968 | 1/20 | 0.59 |
| ▸ | FLT3 | P36888 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | MYLK | Q15746 | 1/20 | 0.59 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29454776 | 0.90 | P2RX1 (1.00) | P2RX1TMPRSS4P2RX4P2RX7KCNMA1 | |
| SCHEMBL2169619 | 0.90 | P2RX1 (1.00) | P2RX1TMPRSS4P2RX4P2RX7KCNMA1 | |
| SCHEMBL18341044 | 0.88 | P2RX1 (0.77) | P2RX1TMPRSS4P2RX4P2RX7KCNMA1 | |
| SCHEMBL13812666 | 0.88 | P2RX1 (0.82) | P2RX1TMPRSS4P2RX4P2RX7KCNMA1 | |
| SCHEMBL23685650 | 0.88 | P2RX1 (0.82) | P2RX1TMPRSS4P2RX4P2RX7KCNMA1 | |
| SCHEMBL30692659 | 0.87 | P2RX1 (0.87) | P2RX1TMPRSS4P2RX4P2RX7KCNMA1 | |
| SCHEMBL24438716 | 0.87 | P2RX1 (0.87) | P2RX1TMPRSS4P2RX4P2RX7KCNMA1 | |
| SCHEMBL15889827 | 0.86 | P2RX1 (0.61) | P2RX1TMPRSS4P2RX4P2RX7KCNMA1 | |
| SCHEMBL23675471 | 0.84 | P2RX1 (0.82) | P2RX1TMPRSS4P2RX4P2RX7KCNMA1 | |
| SCHEMBL17845883 | 0.84 | P2RX1 (0.82) | P2RX1TMPRSS4P2RX4P2RX7KCNMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022109148-A1 | SMALL MOLECULE INHIBITORS OF SARS-COV-2 INFECTIONS | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2022-05-27 | — | — | WO | claimed |
| US-20240002332-A1 | Small Molecule Inhibitors of SARS-CoV-2 Infections | THE FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION | 2024-01-04 | — | — | US | disclosed |
| US-20230406831-A1 | COMPOUNDS AND METHODS OF INHIBITING BACTERIAL CHAPERONIN SYSTEMS | THE TRUSTEES OF INDIANA UNIVERSITY | 2023-12-21 | — | — | US | disclosed |
| WO-2022109148-A1 | SMALL MOLECULE INHIBITORS OF SARS-COV-2 INFECTIONS | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022103572-A1 | COMPOUNDS AND METHODS OF INHIBITING BACTERIAL CHAPERONIN SYSTEMS | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2022-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002332-A1 | Small Molecule Inhibitors of SARS-CoV-2 Infections | ACE2, ACE, TMPRSS2 | P2RX1 2669/4885TMPRSS4 14/4885P2RX4 3287/4885 |
| US-20230406831-A1 | COMPOUNDS AND METHODS OF INHIBITING BACTERIAL CHAPERONIN SYSTEMS | HSP90B1, HSPBP1, HSP90AB1 | P2RX1 4633/4885TMPRSS4 3530/4885P2RX4 4679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.